The global market for Major Depressive Disorder (MDD) therapeutics was
valued at $8.7 billion in 2013, and several key patent expiries will
cause it to decline at a negative Compound Annual Growth Rate (CAGR) of
4% to $7.4 billion by 2017.

The decline is due to key patent expiries of blockbuster drugs such as
Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period.
The expected launch of few promising pipeline molecules such as
brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the
key patent expiries. Recently launched Brintellix which has a novel
multimodal mechanism of action and is the only drug which can provide
improvements in cognitive function is expected to lead the market by the
end of forecasting period.

New drug launches after 2017 will reinvigorate the market, which will
increase at a CAGR of 3.5% to $8.1 billion by 2020.

Scope:

A brief introduction to MDD, including the disease's pathophysiology,
etiology, diagnosis and treatment algorithms.

In-depth analysis of currently marketed drugs for MDD, including
analysis of their safety, efficacy, treatment patterns and
strengths/weaknesses. Including a heat map comparing the drugs in
terms of safety and efficacy.

A comprehensive review of the pipeline for MDD, including individual
analysis of a number of late-stage pipeline drugs that are likely to
enter the market during the forecast period. The pipeline is analyzed
on the basis of phase distribution, molecule types, program types,
mechanisms of action and molecular targets.

Multi-scenario forecast data of the market to 2020, taking into
account how the market may be affected by the introduction of new
drugs, the expiry of key patents on current drugs and the changes in
disease epidemiology across the key developed markets.

Discussion of the drivers and barriers for market growth.

In-depth analysis of all licensing and co-development deals that have
occurred in the MDD market since 2006.